Maria-jesus Blanchard

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

Journal: Blood

Published: March 02, 2026

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances

Published: September 18, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances

Published: September 18, 2025

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

Journal: HemaSphere

Published: August 21, 2025

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.

Journal: The Lancet. Haematology

Published: January 22, 2025

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma.

Journal: Blood

Published: April 16, 2024

A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.

A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.

Journal: Cancers

Published: April 08, 2024

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Journal: Haematologica

Published: August 25, 2023

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.

Journal: Cancers

Published: September 16, 2022

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 06, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026